Join to View Full Profile
480 Red Hill RdMiddletown, NJ 07748
Phone+1 848-800-5319
Dr. Mai is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2022 - 2025
Johns Hopkins UniversityResidency, Internal Medicine, 2019 - 2022- Johns Hopkins University School of MedicineClass of 2019
Certifications & Licensure
NJ State Medical License 2025 - 2027
NY State Medical License 2022 - 2027
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- eIF4A controls translation of estrogen receptor alpha and is a therapeutic target in advanced breast cancer.Jacob A Boyer, Ezra Y Rosen, Malvika Sharma, Madeline A Dorso, Nicholas Mai
Proceedings of the National Academy of Sciences of the United States of America. 2025-07-29 - Sequential Antibody-Drug Conjugate Therapy in Patients With Metastatic Breast Cancer Treated With Sacituzumab Govitecan and Trastuzumab Deruxtecan.Nicholas Mai, Miriam M Klar Lieberman, Emanuela Ferraro, Maria Bromberg, Yuan Chen
JCO Precision Oncology. 2025-05-01 - 2 citationsPredictors of response to CDK4/6i retrial after prior CDK4/6i failure in ER+ metastatic breast cancer.Nicholas Mai, Carlos H Dos Anjos, Pedram Razavi, Anton Safonov, Sujata Patil
NPJ Breast Cancer. 2024-10-18
Journal Articles
- Dose dense doxorubicin plus cyclophosphamide in a modified KEYNOTE522 regimen for triple negative breast cancerNicholas Mai et al, NPJ Breast, 2024
- Predictors of Response to CDK4/6i Retrial After Prior CDK4/6i Failure in ER+ Metastatic Breast CancerNicholas Mai et al, NPJ Breast, 2024
- Pathologic complete response to KEYNOTE522 and HER2-directed therapy for synchronous TNBC and HER2+ breast cancerNicholas Mai etal, NPJ Precision Oncology, 2024
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
